Brain: Tumours
The question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of commissioning of the use of Visualase for Inoperable brain tumours on the NHS.
Answered by Ashley Dalton
The decision to commission new services sits with integrated care boards (ICBs), overseen by NHS England. For proposed new treatments which require additional investment, NHS England carries out a relative prioritisation process to determine which services will be routinely commissioned.
NHS England and the National Institution for Clinical Excellence have conducted literature reviews on the effectiveness of MRI-guided laser interstitial thermal therapy (MRgLITT), which includes Visualase, to treat different conditions relating to inoperable brain tumours. Studies have shown very low certainty of treatment success, and it was not possible to draw reliable conclusions about the clinical effectiveness, safety or cost effectiveness of MRgLITT compared with continued medical therapy.
However, the Government is invested in driving new lifesaving and life-improving research, supporting those diagnosed and living with brain tumours. The Department, NHS England, and the National Institute for Health Care and Research (NIHR) are taking several steps to help improve outcomes for brain tumour patients to ensure the most promising research opportunities are made available to adult and child patients.
Furthermore, we will publish a new National Cancer Plan, which will include further details on how we will improve outcomes for cancer patients, including improvement treatment options for cancer patients.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →